<DOC>
	<DOC>NCT00599417</DOC>
	<brief_summary>Primary - To evaluate the efficacy of Pulmonaron in the decrease of interleukin-4/interferon gamma after second period of treatment Secondary - To evaluate the efficacy of Pulmonarom in the prevention of upper respiratory tract infections symptoms through patient evaluation of fever or respiratory presence after second period of treatment - To evaluate loss of working or study days after second period of treatment - To evaluate the safety and tolerability of Pulmonarom in the population under study</brief_summary>
	<brief_title>PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Broncho-Vaxom</mesh_term>
	<criteria>Patients with history of relapse or recurrence of respiratory infections or disease Patients with chronic respiratory disease as asthma, bronchitis or sinusitis Patients unlikely to comply with the protocol, for example, uncooperativeness or impossibility to return for followup visits Patients who are participating or who have participated in another clinical trial during the previous 3 months Patients who have received immunology response stimulants during the previous 30 days Hypersensitivity The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>